Details of the Drug Combination

General Information of Drug Combination (ID: DCKGP57)

Drug Combination Name
REGN3048 REGN3051
Indication
Disease Entry Status REF
Middle East Respiratory Syndrome (MERS) Discontinued [1]
Component Drugs REGN3048   DM0E3ZG REGN3051   DM7LIV2
Antibody Antibody

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of REGN3048
Disease Entry ICD 11 Status REF
Coronavirus infection 1D92 Phase 1 [2]
REGN3048 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
COVID-19 spike glycoprotein (S) TTZ3COY SPIKE_SARS2 Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of REGN3051
Disease Entry ICD 11 Status REF
Coronavirus infection 1D92 Phase 1 [2]
REGN3051 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
COVID-19 spike glycoprotein (S) TTZ3COY SPIKE_SARS2 Inhibitor [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health.
3 Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.